ENO1 and non-small cell lung carcinoma: The existence of immunosuppressive status has been described in NSCLC patients [30], suggesting that the reduction of anti-ENO1 Ab in serum may result from the suppression of anti-ENO1 immune response in late-stage NSCLC patients.